Home | Articles
Wed, 07/19/2017 - 07:51  |  webadmin
Published on:July 2017
Indian Journal of Pharmaceutical Education and Research, 2017; 51(4):597-602
Original Article | doi:10.5530/ijper.51.4.89

Silibinin: An Inhibitor of Mir-181a Gene Expression in Sk-Br-3 Breast Cancer Cell Line


Authors and affiliation (s):

Parvaneh Shahinfar1, Nasrin Motamed2*, Elnaz Birjandian2 and Omid Shabanpour3

1Department of Cell and Molecular Biology, School of Biological Sciences, Kharazmi University, Tehran, IRAN.

2School of Biology, College of Science, University of Tehran, Tehran, IRAN.

3Faculty of Medicine, Shahrood Islamic Azad University of Medicine, Shahrood, IRAN.

Abstract:

Background: Mir-181a has been considered as an attractive molecular target for breast cancer therapy. The main objective of this work is to assess the inhibitory effects of silibinin, a herbal substance, on proliferation, apoptosis and Mir-181a gene expression in human breast cancer cell line SK-BR-3. Materials and Methods: Human breast cancer cell line SK-BR-3 was treated with various concentration of silibinin. Cell viability was assessed by MTT assay and apoptosis by flow cytometry. Expression of human mir-181a gene was measured with real-time PCR. Results: Silibinin inhibits growth of SK-BR-3 cells in a dose- and time-dependent manner and effectively induces apoptosis of SK-BR-3 cells. In addition, silibinin caused a decrease in Mir-181a level. Conclusion: These findings suggest that cell viability along with Mir-181a gene expression in breast cancer cells could be reduced by silibinin. These results suggest that silibinin inhibits the proliferation of SK-BR-3 cells, and it induces apoptosis by down-regulating Mir-181a expression in breast cancer cells.

Key words: Silibinin, Cell Viability, Apoptosis, Sk-Br-3 Cell Line, Mir-181a.

Downloads

 




 

Login to post comments  |  Tags: Apoptosis, Cell viability, Mir-181a., Silibinin, Sk-Br-3 Cell Line

Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the Latest Release of Journal Citation Reports (source: Web of Science Data).

 

Impact Factor® as reported in the 2023 Journal Citation Reports® (Clarivate Analytics, 2023): 0.8

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.

DOI HISTORY

IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs

 

Indian Journal of Pharmaceutical Education and Research is an official Publication of Association of Pharmaceutical Teachers of India, Bangalore. The journals and its contents are licensed under a Creative Commons Attribution-Non Commercial-No Derivs 4.0 License. Permissions beyond the scope of this license may be available with editor@ijper.org

Ind.J Pharm.Edu. Res. [http://www.ijper.org]
[ISSN:0019-5464] EMANUSCRIPT Services